Pathology
19/03/2026 11:55
March 19 (Reuters) - CervoMed Inc CRVO.O: CERVOMED ANNOUNCES NEW DATA AT THE AD/PD™ 2026 SCIENTIFIC CONFERENCE THAT REINFORCE NEFLAMAPIMOD’S POSITIVE EFFECTS IN DEMENTIA WITH LEWY BODIES (DLB) IN PATIENTS WITHOUT ALZHEIMER’S DISEASE CO-PATHOLOGY Source text: ID:nGNX6fkxhq Further company coverage: CRVO.O ((((Reuters.Briefs@thomsonreuters.com;));))